Postmenopausal Alopecia (Hair Loss)

Oct 7, 2017 by in GYNECOLOGY Comments Off on Postmenopausal Alopecia (Hair Loss)

Cycle Changes in the hair follicle Duration Anagen Growing phase 6 years Catagen Involutional phase 3 weeks Telogen Resting phase 3 months Hair loss is divided into two broad types,…

read more

Nonhormonal Pharmacotherapies for Menopause Management

Oct 7, 2017 by in GYNECOLOGY Comments Off on Nonhormonal Pharmacotherapies for Menopause Management

Fig. 3.1 Menopausal hot flash etiology – proposed model (WS warm sensing; NKB neurokinin B; KNDy kisspeptin, neurokinin B, dynorphin; GnRH gonadotropin-releasing hormone; 5HT serotonin; NE norepinephrine; GABAergic gamma-aminobutyric acidergic)…

read more

Management Strategies for Sexual Health After Breast Cancer Diagnosis

Oct 7, 2017 by in GYNECOLOGY Comments Off on Management Strategies for Sexual Health After Breast Cancer Diagnosis

© Springer International Publishing Switzerland 2017Lubna Pal and Raja A. Sayegh (eds.)Essentials of Menopause Management10.1007/978-3-319-42451-4_19 19. Management Strategies for Sexual Health After Breast Cancer Diagnosis Eve Overton1  , Erin Hofstatter2, Devin Miller3 and Elena Ratner3 (1) Yale University School of…

read more

Hormonal Therapy for Menopausal Symptoms in Gynecologic Cancer Survivors

Oct 7, 2017 by in GYNECOLOGY Comments Off on Hormonal Therapy for Menopausal Symptoms in Gynecologic Cancer Survivors

© Springer International Publishing Switzerland 2017Lubna Pal and Raja A. Sayegh (eds.)Essentials of Menopause Management10.1007/978-3-319-42451-4_17 17. Hormonal Therapy for Menopausal Symptoms in Gynecologic Cancer Survivors John Durfee1   (1) Department of Obstetrics and Gynecology, Boston University School…

read more

Bothersome Vasomotor Symptoms: Management in Women with Type 2 Diabetes Mellitus (Case 1) and Differential Diagnostic Considerations (Case 2)

Oct 7, 2017 by in GYNECOLOGY Comments Off on Bothersome Vasomotor Symptoms: Management in Women with Type 2 Diabetes Mellitus (Case 1) and Differential Diagnostic Considerations (Case 2)

FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 ha 2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT. The test should be…

read more
Get Clinical Tree app for offline access